vTv Therapeutics Files 8-K for Material Agreement
Ticker: VTVT · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1641489
| Field | Detail |
|---|---|
| Company | Vtv Therapeutics Inc. (VTVT) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $15, $0, $22, $80 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, material-agreement, financials
TL;DR
vTv Therapeutics filed an 8-K on 8/29/25 for a material agreement. Check it out.
AI Summary
On August 29, 2025, vTv Therapeutics Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, incorporated in Delaware, is involved in pharmaceutical preparations and is headquartered in High Point, NC.
Why It Matters
This filing indicates a significant business development or financial event for vTv Therapeutics, requiring disclosure to investors.
Risk Assessment
Risk Level: low — This is a standard regulatory filing (8-K) that reports a material definitive agreement and financial statements, not an event that inherently increases risk.
Key Numbers
- 001-37524 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-3916571 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- vTv Therapeutics Inc. (company) — Registrant
- August 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- High Point, NC (location) — Principal Executive Offices
- 2834 (sic_code) — Standard Industrial Classification
FAQ
What is the nature of the material definitive agreement filed by vTv Therapeutics?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 29, 2025.
Where are vTv Therapeutics' principal executive offices located?
vTv Therapeutics' principal executive offices are located at 3980 Premier Drive, Suite 310, High Point, NC 27265.
What is vTv Therapeutics' Standard Industrial Classification (SIC) code?
vTv Therapeutics' SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 1,247 words · 5 min read · ~4 pages · Grade level 12.3 · Accepted 2025-09-02 09:00:17
Key Financial Figures
- $0.01 — stered Class A Common Stock, par value $0.01 per share VTVT Nasdaq Capital Marke
- $15 — ts were sold at a per-Unit price of (x) $15.265, in the case of Units including a S
- $0 — Pre-Funded Warrants are exercisable for $0.01, at any time after their original is
- $22 — e. The Warrants are exercisable for (x) $22.71, if exercised for a Share, or (y) $2
- $80 m — the Private Placement of approximately $80 million, before deducting estimated offer
Filing Documents
- d52598d8k.htm (8-K) — 33KB
- d52598dex41.htm (EX-4.1) — 74KB
- d52598dex42.htm (EX-4.2) — 153KB
- d52598dex101.htm (EX-10.1) — 151KB
- d52598dex102.htm (EX-10.2) — 127KB
- 0001193125-25-193486.txt ( ) — 799KB
- vtvt-20250829.xsd (EX-101.SCH) — 3KB
- vtvt-20250829_lab.xml (EX-101.LAB) — 18KB
- vtvt-20250829_pre.xml (EX-101.PRE) — 11KB
- d52598d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 4.2 Form of Warrant. 10.1 Securities Purchase Agreement, dated August 29, 2025, by and among vTv Therapeutics Inc. and the investors party thereto. 10.2 Registration Rights Agreement, dated August 29, 2025, by and among vTv Therapeutics Inc. and the investors party thereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VTV THERAPEUTICS INC. Date: September 2, 2025 By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: President and Chief Executive Officer